看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
! i5 e% z+ [, O8 y1 [7 z! X7 J: o; E' q8 l* M: T/ L
5 \$ C% ~7 }' c: JCurrently available feasibility data for possible combination strategies.
* M' q$ p) `. B- q( O; o2 T6 F# X* B8 `————————————————————————————————" C# K) w. l0 y( ~% T% q* {
Combination Feasibility according to preliminary data 9 K! X1 T% s% o( e' }; o+ X
——————————————————————————————————
9 x7 ^* O. y/ m4 J5 Z' m) bBevacizumab + sorafenib Yes, reduced dose - r7 ?" J$ Y1 h" J) E) C# p
Bevacizumab + sunitinib† No
2 F5 t# l: Z( F$ w- H6 ZBevacizumab + temsirolimus Yes
4 k# x7 c4 v/ ~7 W* P: S% hBevacizumab + everolimus Yes - T* J0 ~% { F; |
Sorafenib + sunitinib ?
+ q# d- {0 _/ L& m5 V6 {Sorafenib + temsirolimus Yes, reduced dose * o v) M( t! g K! Q! d
Sorafenib + everolimus Yes, reduced dose 5 a$ Z% K) T5 B
Sunitinib + temsirolimus† No
% P6 P6 [9 f J9 R2 TSunitinib + everolimus ?
6 c9 q; Z) v2 P2 wTemsirolimus + everolimus ? 1 Q3 G& p6 A( V# U( {, Q
————————————————————
7 O- S. r4 q, i+ D- \" m& c†Led to US FDA warning.0 u* Z- S% D0 r5 z
?: As yet unattempted combination.
$ F% _+ V* w0 {# W" `7 i2 }0 K: k |